A combination of mTOR inhibitor, ridaforolimus and novel AKT inhibitor, MK-2206, showed activity in heavily pretreated hormone positive and negative breast cancer patients who exhibit PI3K pathway dependence, based on low RAS signature score. The combination was well tolerated in a phase I study, according to Dr Shilpa Gupta of the Lee Moffitt Cancer Center, Tampa, USA.

Read the article in full here.

Source: ESMO